<DOC>
	<DOCNO>NCT00941655</DOCNO>
	<brief_summary>Background : - Gastric ( stomach ) cancer rare cancer . In case , time diagnose spread organ body chance cure small . The standard treatment gastric cancer combination chemotherapy drug . - Researchers interested find surgically remove tumor begin chemotherapy stomach cancer slow halt spread well give chemotherapy alone . Objectives : - To determine whether tumor removal surgery follow chemotherapy effective treat gastric cancer chemotherapy give alone . Eligibility : - Patients 18 year age old diagnose gastric cancer . Design : - All patient undergo initial physical examination , blood test , image scan , laparoscopy determine extent disease . - Half participant assign surgery first chemotherapy ; half assign chemotherapy alone . - The surgery-plus-chemotherapy group major surgery remove tumor stomach abdominal area , follow recovery time 4 week . Chemotherapy begin 6 8 week surgery . - The chemotherapy-only group begin treatment within 2 week laparoscopy . - All patient receive four chemotherapy drug : 5-Fluorouracil , leucovorin , oxaliplatin , irinotecan . The drug give intravenously 2 day every 2 week ( one cycle ) 12 cycle ( 6 month ) , either National Institutes Health ( NIH ) Clinical Center home refer oncologist . Patients surgery group tumor peritoneum receive additional set chemotherapy drug separate treatment . - During chemotherapy cycle , patient provide blood sample approximately week physical examination scan regular basis . - Patients return NIH Clinical Center follow-up visit every 4 month 2 year , every 6 month 3 year yearly thereafter .</brief_summary>
	<brief_title>Prospective Randomized Trial Comparing Gastrectomy , Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone : GYMSSA Trial</brief_title>
	<detailed_description>Background : - The standard care metastatic gastric cancer ( MGC ) systemic therapy result median survival 6-12 month rare survivor three year . - For patient limited MGC , retrospective study show improved overall survival follow gastrectomy and/or metastasectomy plus systemic therapy ( e.g . median survival liver resection metastatic gastric cancer 15-37 month , five year survival rate 25 % ) . - This prospective randomize trial patient MGC limit metastasis design compare two therapeutic approaches-gastrectomy metastasectomy plus systemic therapy ( GYMS ) vs. systemic therapy alone ( SA ) -- evaluate outcome light selection criterion define patient may benefit aggressive approach . Objectives : Primary Objective : - To compare two therapeutic approach -- GYMS vs. SA -- term overall survival patient limited MGC . Secondary Objectives : - To analyze selection criterion patient might benefit GYMS approach . - To determine progression-free survival arm . Eligibility : - MGC limited metastatic disease think resectable evidence disease . - 18 year old great Eastern Cooperative Oncology Group ( ECOG ) 0-2 - Laboratory physical examination parameter within acceptable limit standard practice guideline prior surgery Design : - Patients randomized receive gastrectomy metastasectomy follow systemic chemotherapy ( GYMS ) systemic chemotherapy ( SA ) alone stratify base site metastatic disease , previous therapy disease free interval . - Patients arm receive FOLFOXIRI regimen ( 5-FU , leucovorin , oxaliplatin irinotecan ) - No cross allow . - Survival analysis do intention treat fashion time randomization . - Based estimated 12 20 month overall survival SA GYMS arm respectively , 68 patient per arm ( power=0.80 , 0.05 two-tailed log-rank test ) enrol . Patients recruit 6 year follow additional 2 year date entry last patient .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Histologically cytologically confirm gastric adenocarcinoma . 2 . Metastatic disease must measurable computed tomography ( CT ) and/or magnetic resonance imaging ( MRI ) Or There must history positive peritoneal washing carcinomatosis 3 . All disease deem resectable negative margin ( NED ) base image study . Note : Patients pulmonary peritoneal metastasis enrol discretion Principal Investigator . Esophageal invasion &lt; 4cm require thoracotomy ( Seiwert II III lesion ) . Hepatic metastasis ( unilateral bilateral less equal 5 lesion , less equal 15 cm total diameter ) . Primary peritoneal metastasis ( small disease load less equal P2 disease ) without massive ascites intestinal obstruction . Paraaortic lymph node metastasis ( station 16 a1 and/or b2 ) . Lung metastases ( less equal 3 unilateral/bilateral , 9 cm total diameter ) . Patients present hepatic peritoneal metastasis must evidence extensive paraaortic/retropancreatic lymph node metastasis . 4 . Greater equal 18 year age . 5 . Must able understand sign Informed Consent Document . 6 . Clinical performance status Eastern Cooperative Oncology Group ( ECOG ) less equal 2 . 7 . Life expectancy great three month . 8 . Patients gender must willing practice birth control four month receive chemotherapy . 9 . Hematology : Absolute neutrophil count great 1300/mm^3 without support Filgrastim . Platelet count great 75,000/mm^3 . Hemoglobin great 8.0 g/dl . 10 . Chemistry : Serum alanine aminotransferase ( ALT ) /aspartate aminotransferase ( AST ) less equal 5 time upper limit normal . Except presence obstructive liver metastasis ALT/AST may 10 time upper limit normal . Serum creatinine less equal 1.5 mg/dl unless measure creatinine clearance great 60 mL/min/1.73 m^2 . Total bilirubin less equal 2 mg/dl , except presence obstructive metastasis . Prothrombin time ( PT ) within 2 second upper limit normal ( International Normalized Ratio ( INR ) less equal 1.8 ) . 11 . No history prior/other malignancy within 2 year prior enrollment exception basal cell carcinoma . EXCLUSION CRITERIA : 1 . Prior treatment 5FU , leucovorin , oxaliplatin , irinotecan ( FOLFOXIRI ) ( treatment component separate regimen allowable ) . 2 . Inability tolerate chemotherapeutic agent . 3 . Grade 2 great neuropathy . 4 . Women childbearing potential pregnant breastfeed potentially dangerous effect chemotherapy fetus infant . 5 . Active systemic infection , coagulation disorder major medical illness cardiovascular , respiratory immune system ; myocardial infarction ; cardiac arrhythmia ; obstructive restrictive pulmonary disease . 6 . Brain metastasis history brain metastasis . 7 . Childs B C cirrhosis evidence severe portal hypertension history , endoscopy , radiologic study . 8 . Weight le 40 kg . 9 . Significant ascites , great 1000cc absence peritoneal disease . 10 . History congestive heart failure and/or leave ventricular ejection fraction ( LVEF ) less 40 % . Note : Patients increase risk coronary artery disease cardiac dysfunction ( e.g. , great 65yo , diabetes , history hypertension , elevate lowdensity lipoprotein ( LDL ) , first degree relative coronary artery disease ) undergo full cardiac evaluation eligible demonstrate significant irreversible ischemia stress thallium ejection fraction &lt; 40 % . 11 . Significant chronic obstructive pulmonary disease ( COPD ) chronic pulmonary restrictive disease pulmonary function test ( PFT 's ) indicating forced expiratory volume 1 ( FEV1 ) less 50 % carbon monoxide diffuse capacity ( DLCO ) less 40 % predicted age . Note : Patients shortness breath minimal exertion risk pulmonary disease ( e.g. , chronic smoker ) undergo pulmonary function test eligible FEV1 le 50 % expect .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Gastric Carcinoma</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Liver Tumors</keyword>
	<keyword>Peritoneal Tumors</keyword>
	<keyword>Metastatic Gastric Cancer</keyword>
	<keyword>Stomach Cancer</keyword>
	<keyword>Gastric Cancer</keyword>
</DOC>